Group 1 - The stock price of Shenzhen Textile A (000045) closed at 12.02 yuan on December 26, 2025, reflecting a 0.17% increase from the previous week's price of 12.0 yuan [1] - The highest intraday price reached 12.15 yuan on December 26, while the lowest was 11.83 yuan on December 23 [1] - The current total market capitalization of Shenzhen Textile A is 6.088 billion yuan, ranking 46th out of 92 in the optical and optoelectronic sector and 2892nd out of 5178 in the overall A-share market [1] Group 2 - The fifth extraordinary general meeting of shareholders was held on December 23, 2025, with 215 shareholders and authorized representatives present, representing 255,670,177 shares, which is 50.4756% of the total voting shares [2] - The meeting approved a proposal for the subsidiary to conduct foreign exchange hedging business, with 99.7590% of A-share shareholders and 100.0000% of B-share shareholders voting in favor [2][3] - Guangdong Zhuojian Law Firm provided a legal opinion confirming that the meeting's procedures and voting results were in compliance with relevant laws and regulations [2]

Group 1 - The company announced a plan to use up to 400 million USD of its own funds for foreign exchange hedging activities within the next 12 months [2] - The hedging activities will include forward foreign exchange settlements and options to mitigate risks associated with fluctuations in the USD and EUR exchange rates [2] - The funds used for these activities will not involve raised capital and the amount can be used repeatedly [2]

（文章来源：证券日报） 证券日报网讯 12月26日，泰恩康发布公告称，2025 年 12 月 26 日，公司召开第五届董事会第十二次会 议审议通过《关于开展外汇套期保值业务的议案》，同意公司及子公司开展外汇衍生品交易，预计任一 交易日持有的最高合约价值金额不超过 4，000 万元人民币或等值外币金额，预计动用的交易保证金和 权利金上限（包括为交易而提供的担保物价值、预计占用的金融机构授信额度、为应急措施所预留的保 证金等）不超过 1，000 万元人民币或等值外币金额。本次开展的外汇衍生品交易业务额度期限为自公 司董事会审议通过之日起 12 个月，在授权期限内该额度可循环使用，期限内任一时点的交易金额（含 前述交易的收益进行再交易的相关金额）将不超过已审议额度，如单笔交易的存续期超过了授权额度期 限的有效期，则授权额度期限的有效期自动顺延至单笔交易终止时止。董事会授权公司董事长在上述额 度范围内行使外汇衍生品业务交易的决策权及签署相关的交易文件，由财务部门负责外汇衍生品业务交 易的具体办理事宜。 ...

Core Viewpoint - Guangdong Taiankang Pharmaceutical Co., Ltd. has announced the approval of a foreign exchange hedging business to mitigate foreign exchange risk, with a maximum contract value of 40 million RMB or equivalent foreign currency per trading day [1][2]. Group 1: Business Overview - The primary purpose of the foreign exchange hedging business is to avoid and prevent foreign exchange rate fluctuations that could negatively impact the company's profits and shareholder equity [2]. - The hedging transactions will be limited to major settlement currencies used in the company's operations, including USD, EUR, and JPY [2]. - The company has set dual limits for the hedging business: a maximum contract value of 40 million RMB or equivalent foreign currency per trading day and a maximum margin and premium of 10 million RMB or equivalent foreign currency [2]. - The authorization for these limits is valid for 12 months from the board's approval date and can be reused within this period [2]. Group 2: Approval Process - The hedging proposal was approved by the company's board of directors on December 26, 2025, and had previously received approval from the audit committee [3]. - The proposal does not require submission to the shareholders' meeting as it falls within the board's decision-making authority [3]. - The board has authorized the chairman to make decisions and sign relevant documents within the approved limits, with the finance department responsible for executing the transactions [3]. Group 3: Risk Control - The company has identified four types of risks associated with the foreign exchange hedging business: market risk, operational risk, performance risk, and legal risk [4]. - To mitigate these risks, the company will implement several control measures, including establishing operational protocols, limiting transactions to actual business needs, and conducting transactions only with qualified financial institutions [4]. - The finance department will oversee daily operations and risk monitoring, with independent directors and the audit department having the authority to supervise compliance [4]. Group 4: Accounting Treatment and Funding Source - The company will account for the foreign exchange derivatives transactions in accordance with relevant accounting standards [5]. - All funding for the foreign exchange hedging business will come from the company's own funds, without involving raised funds or credit [5]. Group 5: Industry Analysis - As a pharmaceutical company, engaging in foreign exchange hedging is expected to stabilize cross-border operating costs, particularly amid increasing global exchange rate volatility, thereby enhancing the company's financial stability and supporting long-term development [6].

Core Viewpoint - Jiahe Intelligent Technology Co., Ltd. is actively engaging in financial management and strategic acquisitions to enhance its operational efficiency and mitigate risks associated with currency fluctuations and cash flow management [1][4]. Group 1: Financial Management Initiatives - The company plans to use up to 800 million RMB or equivalent foreign currency for foreign exchange hedging to mitigate currency risk from exports [3][5]. - Jiahe Intelligent intends to conduct accounts receivable factoring business with a total amount not exceeding 800 million RMB, aimed at optimizing cash flow management [3][4]. - The company will utilize up to 700 million RMB of its own funds and 700 million RMB of idle raised funds for cash management, focusing on high-security, liquid short-term financial products [6][5]. Group 2: Acquisition Plans - Jiahe Intelligent's wholly-owned subsidiary, Cosonic International Pte. Ltd., plans to acquire all limited partnership interests and related shares of beyerdynamic GmbH & Co. KG, with a waiver agreement signed to extend the transaction deadline to April 30, 2026 [2][4]. - The acquisition agreement includes provisions for mutual waiver of rights related to regulatory approvals, allowing for negotiations on extending the waiver period if necessary [2][4]. Group 3: Upcoming Corporate Actions - The company will hold its first extraordinary general meeting of 2026 on January 9, 2026, to discuss the waiver agreement related to the acquisition, requiring a majority vote from shareholders [7]. - The interest payment for the "Jiahe Convertible Bonds" will be made on January 5, 2026, with a coupon rate of 0.40% for the period from January 4, 2025, to January 3, 2026 [8].

截至2025年12月25日收盘，澳柯玛(600336)报收于8.55元，下跌1.84%，换手率3.8%，成交量30.29万 手，成交额2.59亿元。 当日关注点 澳柯玛股份有限公司关于开展远期外汇交易业务的公告 澳柯玛股份有限公司于2025年12月24日召开九届二十次董事会，审议通过《关于公司2026年度开展远期 外汇交易业务的议案》。为应对外汇波动风险，增强财务稳健性，公司及控股子公司拟在2026年度开展 金额不超过10,000万美元（或等值外币）的远期外汇交易业务，主要用于进出口业务的外汇套期保值， 不进行投机交易。交易品种包括外汇远期合约、期权、掉期、货币互换等，交易对手为具备资质的银行 金融机构，合约期限均在一年以内。公司已制定内部控制办法，明确禁止投机行为，并采取多项措施控 制市场、回款预测及法律风险。该事项无需提交股东大会审议。 澳柯玛股份有限公司2026年度日常关联交易预计公告 交易信息汇总 资金流向 12月25日主力资金净流出3381.98万元，占总成交额13.05%；游资资金净流入2017.77万元，占总成交额 7.79%；散户资金净流入1364.22万元，占总成交额5.27%。 公司公告汇 ...

Group 1 - The offshore and onshore RMB against the USD have both reached 14-month highs, with offshore RMB rising 4.4% and onshore RMB rising 3.7% year-to-date, while volatility has dropped to a near ten-year low [1] - The recent appreciation of the RMB is supported by the resilience of the domestic economy and is also driven by the decline of the USD index and the release of year-end settlement demand, boosting market confidence in the RMB's performance [1] - There is a growing optimism in the market regarding the RMB potentially breaking the "7" level against the USD, but it is emphasized that appreciation should be viewed from a multi-dimensional perspective rather than expecting rapid gains [1] Group 2 - Maintaining a stable exchange rate at a reasonable equilibrium level is crucial, as it allows for dual-directional fluctuations and enhanced elasticity, which can mitigate market pressures and prevent speculative capital flows [2] - The path of RMB appreciation may face challenges due to external factors such as the narrowing space for Federal Reserve rate cuts and potential fluctuations in trade policy during the U.S. midterm election year [2] - The internal economic transition is still ongoing, with a dual pressure of expanding trade surplus and insufficient domestic demand, indicating that the RMB exchange rate is in a dynamic adjustment process [2] Group 3 - Over 30 A-share companies have engaged in foreign exchange hedging since December, demonstrating a rational response to exchange rate fluctuations [3] - Regulatory authorities are encouraged to enhance expectation management and macro-prudential oversight, improving the supply of foreign exchange market tools to help companies mitigate exchange rate risks [3] - The appreciation of the RMB reflects economic resilience, but a gradual and steady approach is deemed more sustainable, emphasizing the importance of aligning exchange rates with economic fundamentals rather than pursuing arbitrary numerical breakthroughs [3]

Group 1 - The offshore and onshore RMB against the USD have both reached 14-month highs, with offshore RMB appreciating by 4.4% and onshore RMB by 3.7% year-to-date, while volatility has dropped to a near ten-year low [1] - Over 30 A-share companies have engaged in foreign exchange hedging activities since December, demonstrating a rational response to currency fluctuations [3] - Regulatory authorities are encouraged to enhance expectation management and macro-prudential oversight, providing better support for companies to mitigate exchange rate risks [3] Group 2 - The appreciation of the RMB reflects the resilience of the domestic economy, but a gradual and stable approach is deemed more sustainable than rapid increases [3] - The dual forces of expanding trade surplus and insufficient domestic demand keep the RMB exchange rate in a dynamic equilibrium adjustment process [2] - Companies are advised to focus on core business development and use foreign exchange hedging tools to manage currency mismatch and exchange rate exposure risks [2]

Core Viewpoint - The company, Aidi Tech (301580), plans to conduct foreign exchange hedging activities to mitigate the risks associated with currency fluctuations, with specific limits on transaction values and durations [1][2][4]. Trading Information Summary - On December 23, 2025, Aidi Tech's stock closed at 43.23 yuan, with a slight increase of 0.02%, a turnover rate of 0.73%, a trading volume of 5,250 shares, and a transaction amount of 22.68 million yuan [1]. - The net capital flow on the same day showed a net outflow of 15.21 thousand yuan from main funds, a net inflow of 35.97 thousand yuan from retail investors, and a net outflow of 20.76 thousand yuan from individual investors [1][3]. - There were three block trades on December 23, with institutional net purchases amounting to 232.65 thousand yuan [1][3]. Company Announcement Summary - Aidi Tech's board of directors held a meeting on December 23, 2025, where they approved a proposal to engage in foreign exchange hedging activities to reduce the impact of exchange rate fluctuations on operational performance [1][3]. - The hedging activities will include forward foreign exchange contracts, foreign exchange swaps, and foreign exchange options, primarily involving currencies such as USD, EUR, and JPY [2][4]. - The maximum limit for margin and premiums is set at 15 million yuan or its equivalent in foreign currency, with a maximum contract value of 100 million yuan or its equivalent in foreign currency per trading day [2][4]. - The duration of these hedging activities is effective for 12 months from the date of board approval, and the funding will come from the company's own resources, not involving raised funds [2][4]. Risk Management and Compliance - Aidi Tech has established a management system for foreign exchange derivative hedging transactions to standardize operations and manage risks associated with currency fluctuations [3]. - The system outlines the definition, scope, operational principles, responsibilities, approval authority, operational processes, confidentiality, risk reporting, and information disclosure related to hedging activities [3]. - The company is permitted to engage only with qualified financial institutions for hedging transactions aimed at mitigating currency or interest rate risks, and speculative activities are prohibited [3].

Core Viewpoint - Huabang Health (002004) is actively engaging in financial maneuvers, including a non-public issuance of convertible bonds and increasing its credit lines, to manage its debt and enhance operational liquidity [2][7]. Trading Information Summary - As of December 23, 2025, Huabang Health's stock closed at 4.83 yuan, down 0.62%, with a turnover rate of 1.01%, trading volume of 190,000 shares, and a transaction value of 91.92 million yuan [1]. - On the same day, the net inflow of funds from major investors was 446,680 yuan, while retail investors experienced a net outflow of 491,300 yuan [1]. Company Announcements Summary - The company announced a non-public issuance of convertible bonds not exceeding 1 billion yuan, with a term of up to 3 years, aimed at repaying interest-bearing debts [2]. - The board approved the application for a total credit line of up to 13.154 billion yuan for 2026, with a guarantee limit of 10.274 billion yuan [7]. - The company plans to conduct forward foreign exchange settlement and RMB foreign exchange options trading in 2026, with a total transaction limit of up to 41 million USD to mitigate exchange rate risks [5][6]. Related Transactions Summary - The company approved an increase in expected daily related transactions for 2025, totaling approximately 138.18 million yuan, and for 2026, expected related transactions amount to 1.199 billion yuan, involving multiple related parties [4]. - The pricing of related transactions will be based on market fair prices to ensure the company's independence [4]. Internal Control and Governance Summary - The company revised its independent director work system to ensure independence and proper governance, emphasizing the need for independent opinions on related transactions [7]. - The company has established a management system for the use of raised funds, ensuring that funds are used specifically for designated purposes and not for financial investments [8]. - The company has implemented a decision-making system for related transactions, detailing approval processes and disclosure requirements [9].